Glaxosmithkline Biologicals Sa

Dominique Ingrid Lemoine

Florence Emilie Jeanne Francoise Wauters

Nathalie Marie-Josephe Garcon

Stéphane André Georges Godart

Amina Laanan

Nicolas Moniotte

Jan Poolman

Dominique Boutriau

Carine Capiau

Pierre Michel Desmons

Frédéric Mathot

Laurence Danielle Ghenne

Véronique Henderickx

Veronique Henderickx

Stephane Andre Georges Godart

Composition are described, which are dried under reduced pressure from a liquid mixture comprising an adjuvant comprising a saponin (e.g., such as QS21) in a liposomal formulation wherein the liposomes contain a neutral lipid (e.g., such as a phosphatidylcholine) and a sterol (e.g., such as cholesterol), and, a cryoprotectant that is an amorphous sugar. The adjuvant may further comprises a TLR-4 agonist. The compositions may further comprising an antigen, such as an antigen derived from, HIV,, ntHi or Varicella Zoster Virus. The cryoprotectant is an amorphous sugar or mixture of amorphous sugars, and preferably is a combination of at least two cryoprotectants selected from sucrose, trehalose and dextran. The compositions may further comprise a buffer and/or a surfactant.

Dried composition of saponin in a liposomal formulation with a neutral lipid, a sterol, and a cryoprotectant

The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, the present invention relates to immunogenic compositions and vaccines comprising detoxified pneumolysin adsorbed onto aluminium phosphate and an improved process for the adsorption of detoxified pneumolysin onto aluminium phosphate. It additionally relates to the use of the immunogenic compositions and vaccines in the treatment or prevention ofinfection.

Vaccine

Described herein is the formulation of immunogenic or vaccine compositions comprising neutral lipid liposome based adjuvants, where the composition is suitable for lyophilisation. In particular, the invention relates to lyophilised forms of such immunogenic or vaccine compositions wherein both the immunogen or vaccine antigen and the adjuvant are present in one and the same vial, as well as to the formulation and manufacture of lyophilised forms of such immunogenic or vaccine composition.

Dried saponin liposomal composition

Immunogenic compositions comprising an M72 related antigen, wherein the conductivity of the composition is 13 mS/cm or lower, or the concentration of salts of the composition is 130 mM or lower, and their use in medicine, are provided.

antigenic composition

[object Object]

The present invention relates to methods of reducing flocculation in an immunogenic composition, where said immunogenic composition comprises (a)B capsular polysaccharide or oligosaccharide (PRP) and (b) at least one non-PRP antigen. The invention further relates to kits comprising (i) a first composition comprising aB capsular polysaccharide or oligosaccharide (PRP) and a polyanionic polymer, and (ii) a second composition comprising a non-PRP antigen adsorbed onto an adjuvant with a zero point charge greater than 8.

Polyanionic polymer adjuvants for Haemophilus influenzae B saccharide vaccines

Immunogenic compositions comprising an Rv1196 related antigen, wherein the conductivity of the composition is 13 mS/cm or lower, or the concentration of salts of the composition is 130 mM or lower, and their use in medicine, are provided.

A multi-valent vaccine composition is described comprising a conjugate of the capsular polysaccharide ofb not adsorbed onto an aluminum adjuvant salt, and two or more further bacterial polysaccharides. A multi-valent vaccine composition is also described comprising a whole-cell pertussis component, tetanus toxoid, diphtheria toxoid, Hepatitis B surface antigen, a conjugate of the capsular polysaccharide ofb, and a conjugate of a capsular polysaccharide oftype A or C (or both). Furthermore, a multi-valent vaccine composition is described comprising a whole-cell pertussis component, tetanus toxoid, diphtheria toxoid, and a low dose of a conjugate of the capsular polysaccharide ofb.

Vaccine composition

The present invention provides lyophilised compositions comprising an antigen and a Toll-like receptor (TLR) 9 agonist. Such compositions may be reconstituted into immunogenic compositions for use in vaccination with a carrier selected from the group of particulate carriers consisting of liposomes, mineral salts, emulsions, polymers and ISCOMs. Methods of making immunogenic compositions from the lyophilised compositions of the invention and use of the same in immunisation are also herein provided.

Lyophilised antigen composition

The present invention relates to the field of vaccines, and in particular vaccines comprising antigens of low isoelectric point at pH 7.0, in particular the capsular polysaccharide or oligosaccharide ofB (PRP). Immunogenic compositions and methods of making such compositions are presented in which the PRP is surprisingly protected from immune interference by adding a polyanionic polymer (such as PLG&#x2014;poly-L-glutamic acid) to the composition.

The present invention relates to the field of vaccines, and in particular vaccines comprising antigens of low isoelectric point at pH 7.0, in particular the capsular polysaccharide or oligosaccharide ofB (PRP). Immunogenic compositions and methods of making such compositions are presented in which the PRP is surprisingly protected from immune interference by adding a polyanionic polymer (such as PLG-poly-L-glutamic acid) to the composition.

Growing community of inventors

Rixensart, Belgium

Dominique Ingrid Lemoine